Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.57 |
| ▸ | GAA | P10253 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CTSD | P07339 | 1/20 | 0.47 |
| ▸ | CFTR | P13569 | 1/20 | 0.47 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.46 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2842204 | 0.86 | TSHR (0.57) | HSD17B10GAAMAPTTSHRMAPK1 | |
| SCHEMBL28453510 | 0.84 | MAPK1 (0.42) | HSD17B10GAAMAPTTSHRMAPK1 | |
| SCHEMBL1030835 | 0.83 | HTT (0.58) | HSD17B10MAPTTSHRMAPK1KDM4E | |
| SCHEMBL28453511 | 0.82 | CTSD (0.45) | HSD17B10GAAMAPTTSHRMAPK1 | |
| SCHEMBL31388963 | 0.82 | NR1I2 (0.46) | HSD17B10GAAMAPTTSHRMAPK1 | |
| SCHEMBL9827014 | 0.82 | HSD17B10 (0.47) | HSD17B10GAAMAPTTSHRMAPK1 | |
| SCHEMBL17128303 | 0.81 | CTSD (0.47) | HSD17B10GAAMAPTTSHRMAPK1 | |
| SCHEMBL18315876 | 0.81 | TSHR (0.56) | HSD17B10GAAMAPTTSHRMAPK1 | |
| Methyl 2-Methoxybenzoate SCHEMBL196037 | 0.80 | TSHR (0.69) | HSD17B10GAAMAPTTSHRMAPK1 | |
| Methyl 2-Methoxybenzoate SCHEMBL29702077 | 0.80 | TSHR (0.69) | HSD17B10GAAMAPTTSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1330442-B1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARM LTD (GB) | 2011-01-19 | — | — | EP | disclosed |
| EP-1330442-B1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARM LTD (GB) | 2011-01-19 | — | — | EP | disclosed |
| US-7750006-B2 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2010-07-06 | — | — | US | disclosed |
| US-7750006-B2 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2010-07-06 | — | — | US | disclosed |
| CN-100400518-C | Phthalazinone derivatives | KUDOS PHARM LTD (GB) | 2008-07-09 | — | — | CN | disclosed |
| US-7151102-B2 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-12-19 | — | — | US | disclosed |
| US-20060142293-A1 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-06-29 | — | — | US | disclosed |
| CN-1473154-A | Phthalazinone derivatives | ������ҩ������˾ | 2004-02-04 | — | — | CN | disclosed |
| EP-1330442-A1 | PHTHALAZINONE DERIVATIVES | Kudos Pharmaceuticals Limited (GB) | 2003-07-30 | — | — | EP | disclosed |
| US-20020183325-A1 | Therapy of disease of the human or animal body mediated by poly ADP-ribosyltransferase (PARP) by administering phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2002-12-05 | — | — | US | disclosed |
| US-6284753-B2 | GRAMPOSITVE BACTERIA | MERCK & CO., INC. | 2001-09-04 | — | — | US | disclosed |
| US-6277843-B1 | USEFUL AGAINST GRAMPOSITIVE BACTERIA, I.E., METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS, WITH REDUCED SIDE EFFECTS | MERCK & CO., INC. | 2001-08-21 | — | — | US | disclosed |
| US-20010011086-A1 | CARBAPENEM ANTIBACTERIAL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. | 2001-08-02 | — | — | US | disclosed |
| EP-1086104-A1 | FUSED PHENOXYMETHYL CARBAPENEM ANTIBACTERIALS | Merck & Co., Inc. (US) | 2001-03-28 | — | — | EP | disclosed |
| US-6207823-B1 | ANTIBIOTIC; ANTIBIOTIC RESISTANT INFECTIONS | MERCK & CO., INC. | 2001-03-27 | — | — | US | disclosed |
| EP-1032384-A1 | CARBAPENEM ANTIBACTERIAL COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT | Merck & Co., Inc. (US) | 2000-09-06 | — | — | EP | disclosed |
| EP-1023293-A1 | ARYLOXYMETHYL CARBAPENEM ANTIBACTERIALS | Merck & Co., Inc. (US) | 2000-08-02 | — | — | EP | disclosed |
| WO-1999062907-A1 | FUSED PHENOXYMETHYL CARBAPENEM ANTIBACTERIALS | MERCK & CO., INC. (US) | 1999-12-09 | — | — | WO | disclosed |
| WO-1999020270-A1 | CARBAPENEM ANTIBACTERIAL COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 1999-04-29 | — | — | WO | disclosed |
| WO-1999014217-A1 | ARYLOXYMETHYL CARBAPENEM ANTIBACTERIALS | MERCK & CO., INC. (US) | 1999-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142293-A1 | Phthalazinone derivatives | CBR1, CBR3, PARP2 | HSD17B10 498/4885GAA 4278/4885MAPT 3788/4885 |
| US-20020183325-A1 | Therapy of disease of the human or animal body mediated by poly ADP-ribosyltransferase (PARP) by administering phthalazinone derivatives | PARP1, PARP11, PARP3 | HSD17B10 230/4885GAA 2135/4885MAPT 2544/4885 |
| US-20010011086-A1 | CARBAPENEM ANTIBACTERIAL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | TOP1, NRDC, PAICS | HSD17B10 872/4885GAA 63/4885MAPT 4547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.